Abstract
Twenty-nine evaluable patients with extensively pretreated breast cancer received PALA, a new pyrimidine antimetabolite. The drug was given by intravenous infusion over 60 min, at a daily dose of 2.5 g/m2 for 2 consecutive days. Courses were repeated at 2-week intervals and doses were escalated to toxicity. Two objective partial remissions were observed, lasting for 3 and 4.5 months respectively. Toxic effects were dose-related and consisted mainly of mucocutaneous manifestations, i.e., skin rashes, stomatitis, diarrhea, conjunctivitis and corneal ulcerations. Evidence of antitumor potential in far-advanced disease and lack of myelosuppression point to the need for additional trials of PALA in a more favorable selection of patients with breast cancer.
Publication types
-
Research Support, U.S. Gov't, P.H.S.
MeSH terms
-
Adult
-
Aged
-
Antimetabolites, Antineoplastic / administration & dosage*
-
Antimetabolites, Antineoplastic / adverse effects
-
Aspartic Acid / administration & dosage
-
Aspartic Acid / adverse effects
-
Aspartic Acid / analogs & derivatives*
-
Breast Neoplasms / drug therapy*
-
Digestive System / drug effects
-
Drug Eruptions / etiology
-
Drug Evaluation
-
Female
-
Humans
-
Infusions, Parenteral
-
Middle Aged
-
Neoplasm Metastasis
-
Organophosphorus Compounds / administration & dosage*
-
Phosphonoacetic Acid / administration & dosage*
-
Phosphonoacetic Acid / adverse effects
-
Phosphonoacetic Acid / analogs & derivatives
Substances
-
Antimetabolites, Antineoplastic
-
Organophosphorus Compounds
-
Aspartic Acid
-
sparfosic acid
-
Phosphonoacetic Acid